Vasoactive Intestinal Peptide
From PeptidePlaza, the free peptide reference · Entry #1044 · Nootropic · Sources fetched 2026-09-10 · Editorial standards
Vasoactive Intestinal Peptide (also known as CCRIS 7231, VIP [MI], VASOACTIVE INTESTINAL PEPTIDE (HUMAN)) is a nootropic research peptide. Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.
Vasoactive Intestinal Peptide (VIP) is an endogenous human peptide and neuropeptide that exerts its effects by activating the PACAP subfamily of class B1 G protein-coupled receptors, specifically VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2). These receptors are widely expressed in both the central and peripheral nervous systems, where they play key roles in neuroprotection and immune modulation. VIP also induces vasodilation, reduces arterial blood pressure, enhances myocardial contractility, stimulates glycogenolysis, and relaxes smooth muscles in the trachea, stomach, and gall bladder. It is currently in Phase 3 clinical trials for peripheral T-cell lymphoma, and research explores its roles in various pulmonary diseases and osteoarthritis.
1 Mechanism of action
VIP is a neuropeptide involved in a diverse array of physiological processes through activating the PACAP subfamily of class B1 G protein-coupled receptors: VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2). Abundantly expressed throughout the CNS and peripheral nervous systems where they primarily exert neuroprotective and immune modulatory roles. Also causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth muscle of trachea, stomach and gall bladder
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Lymphoma, T-Cell, Peripheral
3 Chemical and physical properties
| CAS number | 37221-79-7 |
|---|---|
| Molar mass | 3326.8 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
3.1 Amino acid sequence
HSDAVFTDNYTRLRKQMAVKKYLNSILN
4 Research studies (8)
- Vasoactive intestinal peptide
Journal of endocrinological investigation (1986) · Review - Vasoactive Intestinal Peptide-Secreting Tumors: A Review
Pancreas (2019) · Review - Vasoactive intestinal peptide secreting tumour: An overview
World journal of gastrointestinal oncology (2022) · Review - The role of vasoactive intestinal peptide in pulmonary diseases
Life sciences (2023) · Review - Role of vasoactive intestinal peptide in osteoarthritis
Journal of biomedical science (2016) · Review - A Role for Vasoactive Intestinal Peptide Interneurons in Neurodevelopmental Disorders
Developmental neuroscience (2021) · Review - Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
Frontiers in endocrinology (2022) · Review - Vasoactive intestinal peptide in the heart
Annals of the New York Academy of Sciences (1988) · Review
5 Safety and risk profile
5.1 Regulatory status
Vasoactive Intestinal Peptide is currently classified as Phase 3 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Vasoactive Intestinal Peptide (VIP) used for?
- Vasoactive Intestinal Peptide (VIP) is currently in Phase 3 clinical trials for the treatment of peripheral T-cell lymphoma. Research also explores its potential roles in pulmonary diseases and osteoarthritis.
- How does Vasoactive Intestinal Peptide (VIP) work?
- Vasoactive Intestinal Peptide (VIP) functions by activating VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors. This activation leads to various physiological effects, including vasodilation, immune modulation, and neuroprotection.
- What are the physiological effects of Vasoactive Intestinal Peptide (VIP)?
- Vasoactive Intestinal Peptide (VIP) is involved in numerous physiological processes. It causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis, and relaxes the smooth muscle of the trachea, stomach, and gall bladder. It also has neuroprotective and immune modulatory roles.
- Is Vasoactive Intestinal Peptide (VIP) FDA approved?
- Vasoactive Intestinal Peptide (VIP) is currently in Phase 3 clinical trials for peripheral T-cell lymphoma. It has not yet received FDA approval.
7 References
- Vasoactive Intestinal Peptide — compound summary PubChem. View source
- Vasoactive Intestinal Peptide — molecule record ChEMBL. View source
- Vasoactive Intestinal Peptide — protein entry UniProt. View source
- Vasoactive Intestinal Peptide — published literature (8,383 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Vasoactive Intestinal Peptide.
Shares systems and immune pharmacology
A synthetic analog of the endogenous tetrapeptide Tuftsin. Developed by the Russian Institute of Molecular Genetics. Studied for anxiolytic, nootropic, and immunomodulatory effects without sedation or dependence.
Shares stimulates and increases pharmacology
Gastrin is an endogenous human peptide that stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete digestive enzymes.
Shares involved and through pharmacology
Thymopentin is an endogenous human peptide composed of five amino acid residues. It is currently investigational and studied for its role in immune modulation.
Shares blood and involved pharmacology
Bradykinin is an endogenous human peptide involved in various physiological processes, including blood coagulation and inflammation.
Shares increases and activating pharmacology
The first drug that builds bone rather than merely slowing its loss — and it works only because it is given as a daily pulse. Continuous exposure to the same peptide destroys bone instead.
Shares stimulates and physiological pharmacology
A 44-amino acid GHRH analog with a trans-3-hexenoic acid N-terminal modification. FDA-approved for HIV-associated lipodystrophy. The most clinically validated GHRH analog for visceral adipose tissue reduction.